...
首页> 外文期刊>The British Journal of Nutrition >Immune-modulating efficacy of a polyphenol-rich beverage on symptoms associated with the common cold: a double-blind, randomised, placebo-controlled, multi-centric clinical study.
【24h】

Immune-modulating efficacy of a polyphenol-rich beverage on symptoms associated with the common cold: a double-blind, randomised, placebo-controlled, multi-centric clinical study.

机译:富含多酚的饮料对与普通感冒相关的症状的免疫调节功效:一项双盲,随机,安慰剂对照,多中心临床研究。

获取原文
获取原文并翻译 | 示例
           

摘要

In the present study, the immune-modulating efficacy of a polyphenol-rich beverage on symptoms associated with the common cold was evaluated. For this purpose, ninety-eight patients reporting common cold symptoms that began no longer than 24 h before the study intervention were randomly assigned to consume either the test beverage or placebo twice per d for 10 d. The severity of the disease was expressed as the total score of the five cold symptoms 'general feeling of sickness', 'headache and/or joint aches', 'sore throat and/or difficulty swallowing', 'hoarseness and/or cough' and 'stuffy nose/sniffle'. Consequently, the decrease from 10.2 (SD 3.1) points at the beginning to 2.1 (SD 2.7) points by the end of the study in the verum group demonstrated a clear improvement, whereas in the placebo group only a reduction from 10.5 (SD 3.0) to 6.3 (SD 3.8) points could be observed. The mean difference between the groups (primary efficacy criterion) of 3.9 points was highly significant (P < 0.01). At the end of the study there were highly significantly (P < 0.01) more patients in the verum group complaint free than in the placebo group (secondary efficacy criterion). In addition to these self-reported values, several local findings of the physical examination were also significantly improved in the verum group.
机译:在本研究中,评估了富含多酚的饮料对与普通感冒相关的症状的免疫调节功效。为此,有98名报告普通感冒症状的患者开始于研究干预之前的24小时内,被随机分配为每10天每天两次饮用测试饮料或安慰剂。疾病的严重程度表示为五种感冒症状“一般的疾病感”,“头痛和/或关节疼痛”,“咽痛和/或吞咽困难”,“声音嘶哑和/或咳嗽”和“鼻塞/鼻涕”。因此,verum组从研究开始时的10.2(SD 3.1)点降低到研究结束时的2.1(SD 2.7)点,显示出明显的改善,而安慰剂组仅从10.5(SD 3.0)降低。至6.3(SD 3.8)点。两组之间的平均差异(主要疗效标准)为3.9分,差异具有统计学意义(P <0.01)。在研究结束时,与安慰剂组相比,verum组无症状的患者明显多于(P <0.01)患者(次要疗效标准)。除了这些自我报告的值外,verum组的一些身体检查局部发现也得到了显着改善。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号